Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Cielo vs LillyDirect Foundayo

Cielo
Graded #121

Higher grade

vs+2.200000000000003
LillyDirect Foundayo
Graded #165

Lower grade

The verdict

Cielo takes it — 69.4/100 to 67.2/100.

Cielo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Cielo is a compounded-GLP-1-only telehealth platform offering semaglutide and tirzepatide with no brand-name drugs and no TRT, hair, or mental-health add-ons — a focused, single-purpose alternative to…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCielo +4
76
72
Dose & formulationCielo +26
85
59
Clinical oversightCielo +1
79
78
Labs & monitoringCielo +1
53
52
FulfillmentLillyDirect Foundayo +13
67
80
Contract termsLillyDirect Foundayo +35
20
55
Cielo · left barLillyDirect Foundayo · right bar

The numbers

MetricCieloLillyDirect Foundayo
WeighScore69.4/10067.2/100
GradeCC
Scorecard rank#121#165
Semaglutide$149/mo (all doses, compounded)Not disclosed
Tirzepatide$249/mo (all doses, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Cielo

Graded #121 · C

Strengths

  • Among the lowest 3-month bundle prices in compounded GLP-1 ($115/mo semaglutide)
  • Single flat price across all doses simplifies titration planning
  • Corporate address (St. Petersburg, FL) and customer-service phone published

Where it loses points

  • No LegitScript, NABP .pharmacy, or HIPAA badge on the home page
  • Pharmacy partner not named (only 'regulated FDA pharmacy partners')
  • State coverage list not published — can't verify all-50-state availability
  • Clinical care runs through MD Integrations, a shared third-party network used by many brands
  • No brand-name Wegovy or Zepbound option
LillyDirect Foundayo

Graded #165 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard